Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study-Reference-Cited by-同舟云学术

Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study

Published:2022-12-15 Issue:1 Volume:41 Page:67-75
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Ozaki Kai,Hatakeyama Shingo^ORCID,Narita Shintaro,Hata Kenichi,Yanagisawa Takafumi,Tanaka Toshikazu,Togashi Kyo,Hamaya Tomoko,Okamoto Teppei,Yamamoto Hayato,Yoneyama Takahiro,Hashimoto Yasuhiro,Kimura Takahiro,Habuchi Tomonori,Ohyama Chikara

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-022-04237-3.pdf

Reference30 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

2. Kimura T, Egawa S (2018) Epidemiology of prostate cancer in Asian countries. Int J Urol 25(6):524–531. https://doi.org/10.1111/iju.13593

3. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW (2018) Current treatment strategies for advanced prostate cancer. Int J Urol 25(3):220–231. https://doi.org/10.1111/iju.13512

4. Etzioni R, Gulati R (2016) Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2(7):955–956. https://doi.org/10.1001/jamaoncol.2015.6310

5. Akamatsu S, Inoue T, Ogawa O, Gleave ME (2018) Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol 25(4):345–351. https://doi.org/10.1111/iju.13526

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions;Current Opinion in Urology;2023-09-11